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The epithelial-to mesenchymal (EMT) process is increasingly recognized
for playing a key role in the progression, dissemination, and therapy resis-
tance of epithelial tumors. Accumulating evidence suggests that EMT
inducers also lead to a gain in mesenchymal properties and promote malig-
nancy of nonepithelial tumors. In this review, we present and discuss cur-
rent findings, illustrating the importance of EMT inducers in tumors
originating from nonepithelial/mesenchymal tissues, including brain
tumors, hematopoietic malignancies, and sarcomas. Among these tumors,
the involvement of mesenchymal transition has been most extensively
investigated in glioblastoma, providing proof for cell autonomous and
microenvironment-derived stimuli that provoke EMT-like processes that
regulate stem cell, invasive, and immunogenic properties as well as therapy
resistance. The involvement of prominent EMT transcription factor fami-
lies, such as TWIST, SNAI, and ZEB, in promoting therapy resistance and
tumor aggressiveness has also been reported in lymphomas, leukemias, and
sarcomas. A reverse process, resembling mesenchymal-to-epithelial transi-
tion (MET), seems particularly relevant for sarcomas, where (partial)
epithelial differentiation is linked to less aggressive tumors and a better
patient prognosis. Overall, a hybrid model in which more stable epithelial
and mesenchymal intermediates exist likely extends to the biology of
tumors originating from sources other than the epithelium. Deeper investi-
gation and understanding of the EMT/MET machinery in nonepithelial
tumors will shed light on the pathogenesis of these tumors, potentially pav-
ing the way toward the identification of clinically relevant biomarkers for
prognosis and future therapeutic targets.
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1. Introduction
The ability of epithelial cells to lose their defining
epithelial features and gaining a more loosely oriented
mesenchymal phenotype is known as the process of
epithelial/mesenchymal transition (EMT). EMT has
been well described during embryonic development
and is an essential process required for the formation
of mesoderm and the neural tube (Kalluri and
Weinberg, 2009; Thiery et al., 2009). In organisms,
EMT plays a role in wound healing and tissue fibrosis.
Upon EMT, cell polarity and cell–cell adhesion are
lost and cells gain a migratory and invasive phenotype
that is characteristic for mesenchymal cells.
In cancer, a key role for EMT in tumor progression
has been proposed (Thiery, 2002). Over the last dec-
ade, accumulating evidence has indicated an important
role for EMT in various malignant properties of tumor
cells including tumor infiltration, metastasis, cancer
stem cell (CSC) properties, therapy resistance, and
immunosuppression (De Craene and Berx, 2013; Yang
and Weinberg, 2008; Ye and Weinberg, 2015). In gen-
eral, the mesenchymal state of tumor cells, character-
ized by cell autonomous motility and invasiveness, has
been associated with worse clinical prognosis. In
essence, EMT is a reversible process and cells can
revert back to an epithelial state by mesenchymal/ep-
ithelial transition (MET) that appears to be essential
for colonization of tumor cells at distant sites, a key
step in the metastatic process. Of note, cells display
plasticity to the EMT/MET processes and may possess
intermediate features of these two opposite states (Ye
and Weinberg, 2015). In fact, recent reports indicate
the existence of cells with a stable hybrid epithelial/
mesenchymal (E/M) status simultaneously expressing
epithelial and mesenchymal markers. E/M is character-
ized by weak cell adhesions, migration in multicell
aggregates giving rise to circulating tumor cells,
enhanced stemness, and therapy resistance (reviewed in
Jolly et al. 2015). Each of the three phenotypes of
EMT, epithelial, hybrid, and mesenchymal, seems to
take on distinct responsibilities during cancer progres-
sion, indicating the complexity of this process and the
challenge to find efficient therapies to comprehensively
combat tumor metastasis (for schematic representa-
tion, see Fig. 1).
The initiation of EMT and maintenance of a mes-
enchymal state is controlled by multiple heterotypic
signals and is context dependent (Nieto and Cano,
2012). During tumor progression, cell autonomous
triggers as well as paracrine signals derived from stro-
mal cells such as fibroblasts and immune cells regulate
the EMT status. The cell intrinsic molecular mecha-
nisms of EMT have been examined extensively and
consist of complex and overlapping signaling net-
works. The hallmark of EMT is loss of the cell adhe-
sion glycoprotein E-cadherin, encoded by the CDH1
gene, leading to the loss of intercellular junctions/cell–
cell interactions and alterations in intermediate fila-
ment composition from cytokeratins to vimentin,
allowing cells to dissociate and gain migratory poten-
tial. The enhanced secretion of proteases, particularly
the matrix metalloproteinases (MMPs), facilitates
extracellular matrix degradation and cell invasion.
Fig. 1. Hybrid and reciprocal phenotypes of EMT/MET. Schematic representation of reciprocal phenotypic conversion of epithelial (E), hybrid
epithelial/mesenchymal (E/M), and mesenchymal (M) phenotypes of cancer cells.
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A number of key EMT transcription factors (EMT-TFs)
have been identified that directly control E-cadherin
expression through transcriptional repression of
CDH1. These include the SNAIL/SNAI1, SLUG/
SNAI2, E47, and zinc finger E-box-binding homeobox
(ZEB) family of EMT-TFs, whereas other TFs like
TWIST and goosecoid are indirect CDH1 suppressors
(Thiery and Sleeman, 2006). The regulation and acti-
vation of the EMT-TFs is complex involving pleiotro-
pic and contextual signals and different regulatory
layers including negative feedback loops with micro-
RNAs (miRNAs) and alterations in the DNA methy-
lation status, facilitating short time or prolonged
induction of the mesenchymal state.
Logically, EMT has been particularly studied in car-
cinomas (epithelial tumors) where it can be locally and
time dependently activated to generate tumor cells
with enhanced aggressive mesenchymal properties.
Much less is known about the role of EMT/MET-
related processes in nonepithelial tumor types such as
gliomas, hematopoietic malignancies, and sarcomas.
Theoretically, the occurrence of an EMT-like process
in gliomas might be expected considering their origin
from primitive epithelium, the neuroectoderm. How-
ever, sarcomas and hematological malignancies main-
tain a mostly mesenchymal status as they originate
from muscle or blood cells, respectively, tissues that
are derived from the embryonic mesoderm. In this
review, we will discuss the current insights into the
contribution of EMT/MET-like processes and underly-
ing mechanisms to the development and progression of
nonepithelial tumor types.
2. MT in tumors of the central nervous
system
During embryonic development before the onset of
neurogenesis, the neural plate is formed of a single
layer of highly undifferentiated neuroepithelial cells.
These neural stem cells (NSC) can differentiate into
the three cell types of the brain: neurons, astrocytes,
and glial cells. Neurogenesis is also ongoing in distinct
areas of the adult brain such as the subventricular
zone (SVZ), the olfactory bulb, or the dentate gyrus of
the hippocampus (G€otz and Huttner, 2005). Although
neural tissue does not originate from a classical epithe-
lial background, accumulating evidence indicates that
molecular drivers of epithelial cell differentiation take
on similar responsibilities in the brain, particularly
during tumor development. Below, we summarize the
current understanding on how the EMT-like process is
regulated in brain tumors and discuss its utility as a
therapeutic and diagnostic target.
2.1. Glioblastoma
Glioblastoma (GBM) is the most common and highest
malignant primary brain cancer in adults with an aver-
age patient survival of less than two years (Stupp
et al., 2005). GBM, characterized by high invasive
growth and high degree of cellular/genetic heterogene-
ity, accounts to the most lethal tumors overall (Siegel
et al., 2015). The field of mesenchymal transition (MT)
research in GBM has attracted significant attention.
The core findings are discussed below and summarized
in Fig. 2.
2.1.1. MT in maintenance of neural and GBM stem
cells
A tight link between a cellular gain of mesenchymal
properties and CSCs has been observed in various
tumors including GBM (Liu and Fan, 2015). CSCs are
considered to be responsible for tumor occurrence,
progression, and emergence of resistance against thera-
peutic interventions (Lathia et al., 2015). Several
prominent members of the EMT network have been
identified to contribute to the CSC pool in GBMs. For
example, ZEB1 promotes the expression of NCS mark-
ers and the chemoresistance marker O6-alkylguanine
DNA alkyltransferase (MGMT), thereby facilitating
GBM tumorigenicity and resistance against temozolo-
mide (TMZ), the standard-of-care chemotherapeutic
today (Siebzehnrubl et al., 2013).
Phylogenetically conserved stem cell signaling path-
ways represent the most accepted anti-CSC targets in
various tumors including GBM (Kahlert et al., 2017;
Takebe et al., 2015). Interfering with such pathways
has been shown to affect MT in GBMs. As such,
WNT signaling controls GBM invasion at least in part
through the initiation of MT (Bhuvanalakshmi et al.,
2015; Duan et al., 2015; Jin et al., 2011; Kahlert et al.,
2012). Forkhead box M1 (FoxM1) promotes glioma
tumorigenicity through the WNT pathway partly by
inducing EMT (Wang et al., 2015a; Zhang et al.,
2011). Targeting the Sonic Hedgehog (SHH) pathway
at the level of Smoothened suppresses glioma malig-
nancy by upregulating miR200 and consequently
blocking ZEB1 (Fu et al., 2013). In addition, SHH/
glioma-associated oncogene homolog 1 (Gli1) signaling
promotes GBM cell invasion by the induction of
EMT-TF SNAI1 (Wang et al., 2010). Recently,
Jagged1 ligand-mediated Notch pathway activation
has been shown to promote MT in gliomas
(Katz et al., 2014). However, currently pharmacologi-
cal studies that make use of, for example, c-secretase
inhibitors to further demonstrate the concept that
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Notch activity controls MT in GBMs are lacking. Fur-
thermore, transcriptional coactivator with PDZ-bind-
ing motif (TAZ), which is primarily regulated through
the developmental conserved stem cell pathway Hippo,
induces mesenchymal differentiation in GBM and
NSC cells and promotes tumor aggressiveness (Bhat
et al., 2011).
Independent of developmental conserved stem cell
pathways, c-MET signaling induces the reprogram-
ming of glioma cells into CSCs (Li et al., 2011). More-
over, c-MET was recently found to promote MT
featuring enhanced MMP activation and cadherin
cleavage as well as fostering resistance against TMZ
(Huang et al., 2016).
The concept that MT in cells of the central nervous
system (CNS) is intertwined with stemness is sup-
ported by discoveries in developmental biology. ZEB1
expression is high in stem cell-rich embryonic brain
but fades during maturation (Koch et al., 2016). ZEB1
controls invasion of human NSC of the SVZ (Kahlert
et al., 2015), proliferation of spinal cord stem cells of
adult mice (Sabourin et al., 2009), and restricts differ-
entiation of murine granular neuron precursors (GNP)
(Singh et al., 2016). Moreover, transforming fetal NSC
into invasive tumorigenic cells leads to the induction
of an MT signature featuring high SNAI1 expression
(Mao et al., 2013).
Taken together, several studies have revealed that
CSC properties in GBM are linked with the MT net-
work. Targeting MT thus can be an efficient way to
eradicate CSCs particularly when interfering with
ZEB1 signaling as SNAI1 was reported to play diver-
gent roles in stemness and MT. It is reported that
SNAI1 in GBM cells promotes invasion but has a neg-
ative effect on tumorigenicity, consistent with the ‘go
or grow’ hypothesis (Han et al., 2011; Savary et al.,
2013). The fact that EMT-TFs also regulate various
processes in non-neoplastic CNS stem cells further
supports the existence of a stem cell/MT axis during
neuro-oncogenesis.
Fig. 2. Regulators of MT in glioblastoma. Schematic representation of the complex molecular interactions of MT in glioblastoma including
its relationship to cancer stem cells (CSCs), neural stem cells (NSCs). MT can be influenced through epigenetics, microenvironmental
stimuli, long noncoding RNAs (lncRNAs) or as a response to therapy.
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2.1.2. Regulators of MT and GBM progression
Several reports have further highlighted the relevance
of MT in the progression of GBM. ZEB2 is upregu-
lated in GBM cells and suppression of ZEB2 inhibits
invasion (Qi et al., 2012) and results in a blockade of
resistance against vascular endothelial growth factor
(VEGF), which involves inhibition of a hypoxia-indu-
cible factor (HIF)1a-ZEB2-EphrinB2 MT pathway
(Depner et al., 2016). Similarly, TWIST1 is highly
expressed in GBM and is involved in promoting cellu-
lar invasion (Elias et al., 2005; Mikheeva et al., 2010).
The Janus kinases (JAKs) and signal transducer and
activator of transcription (STAT) proteins, particularly
STAT3, are among the most promising targets for can-
cer therapy (Yu et al., 2014). STAT3 signaling has
been identified as a core driver of mesenchymal trans-
differentiation in GBMs (Carro et al., 2010). STAT3
assists in GBM cell invasion by inducing SNAI1 and
activation of MMPs (Priester et al., 2013). Recent
work suggests that mesenchymal transformation by
STAT3 is controlled through Annexin-A2 (ANXA2)
that is inactivated in GBMs that exhibit mutations in
the isocitrate dehydrogenase (IDH) gene (Kling et al.,
2016).
Interestingly, STAT3 may also suppress the recogni-
tion of GBM cells by the immune system (Ciaglia
et al., 2015). Recent observations suggest that cellular
metabolic adaptations such as in choline homeostasis
or autophagy can trigger or support the induction of
mesenchymal transcription factors in GBM (Koch
et al., 2016; Zou et al., 2016).
Overall, accumulating evidences occur that a variety
of potent oncogenic signaling pathways contribute to
MT in GBMs.
2.1.3. Tumor microenvironment regulators of MT
The tumor microenvironment (TME), consisting of
blood vessels, immune cells, and fibroblasts, is a potent
influence for a variety of cellular processes and has
been observed to promote mesenchymal transforma-
tion in different contexts (Cooper et al., 2012). The
impact of the TME on MT in GBM is discussed
below.
Transforming growth factor beta (TGF-b), most
often produced by immune cells and microglia, is a
prominent therapeutic target in GBM and has been
investigated both in preclinical and in clinical studies
(Joseph et al., 2013). Exogenously added TGF-b
induces ZEB1 leading to increased invasiveness, and
targeting TGF-b signaling can block MT in GBMs
(Joseph et al., 2014). Moreover, in GBM xenografts
and patient samples, evidence for local TGF-b-depen-
dent MT was provided. In another study, TGF-b2
transcript levels were demonstrated to serve as a pre-
dictive marker for inferior patient overall survival
(Frei et al., 2015). At the cell surface, the Fas receptor
(CD95) has recently been associated with CSC and
MT properties in GBM cells, involving activation of
PI3K signaling (Drachsler et al., 2016).
Shortage of blood supply leads to hypoxia (< 5%
oxygen tension) and is a characteristic neuropathologi-
cal hallmark of GBM. ZEB1 is active in hypoxic pseu-
dopalisades that surround necrotic areas and exposure
to low oxygen augments invasive properties of glioma
cells through the induction of EMT activators (Depner
et al., 2016; Joseph et al., 2015; Kahlert et al., 2015;
Xu et al., 2015). Given this unequivocal correlation
between low oxygen and GBM MT, therapies that aim
to block tumor oxygenation such as through blocking
VEGF signaling can have contraintended consequences
and induce tumor malignancy through the activation
of MT (Piao et al., 2012). Of note, VEGF signaling
has been shown to directly augment GBM cell inva-
sion upstream of MT signaling, and this network is
activated in an oxygen-dependent manner, further rais-
ing concerns for the use of anti-VEGF therapy in
GBM. The study by Piao et al. also indicates that the
activation of the local immune cell environment in
response to therapy may promote the mesenchymal
shift. Confirming data comes from another study
showing that GBM-associated immune cells produce
high levels of TGF-b, which causes activation of
MMPs in the tumor cells to enhance invasion
(Ye et al., 2012). Given the current rise of immune
therapeutic interventions as an innovative treatment
avenue in cancer, including GBM, caution needs to be
drawn on potential unintended effects such as inducing
dissemination of a subset of tumor cells with
mesenchymal features.
In conclusion, TME-derived signals appear to be of
key importance in controlling the mesenchymal status
of GBM.
2.1.4. MT and response to therapy
Cancer cells are characterized by high plasticity having
the ability to adapt to alterations in their microenvi-
ronment to overcome cellular stress such as that
inflicted by therapeutic treatment. Some indications
have been obtained that standard therapies can cause
a selection for therapy-resistant cells that have under-
gone MT or lead to the initiation of MT. Treatment
with radioactive iodine-125 (125I) inhibited ZEB1 and
MT accompanied by reduced cellular invasion and
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growth (Tian et al., 2015). GBM cells with an MT sig-
nature are less affected by standard treatments. For
example, following c-radiation of patients SNAI1,
EMT markers and invasion were elevated in recurrent
GBM samples, and in vitro, SNAI1 knockdown pre-
vented radiation-induced MT leading to reduced cellu-
lar invasion (Mahabir et al., 2014). Radiation was
also found to activate NF-jB/STAT3 cooperative sig-
naling that was linked to increased expression of inter-
cellular adhesion molecule-1 (ICAM-1) and cell
invasion (Kesanakurti et al., 2013). The standard
chemotherapeutic TMZ was reported to select for
GBM cells with different properties than the parental
cells including an increase in migration and invasion
and upregulation of EMT markers like SNAI1 and
SNAI2 (Stepanenko et al., 2016). As earlier men-
tioned, treatment with the VEGF inhibitor causes MT
in a hypoxia-dependent manner eventually establishing
therapy-resistant cells (Piao et al., 2013). Interestingly,
various plant-derived compounds can also efficiently
impair glioma cell invasion through suppression of
MT. The spermine derivative kukoamine A causes
cytotoxicity and inhibits motility by inducing apopto-
sis and blocking EMT-TFs such as SNAI1 (Wang
et al., 2016). Members of anthocyanidins, a class of
polyphenols, have been reported to effectively regulate
MT in GBM cells, thereby providing a molecular link
on how fruit and vegetable-rich diet has the potential
to fight tumor cell dissemination. As such, delphinidin
inhibits TGF-b signaling to block SNAI1 and invasion
of U87 GBM cells (Ouanouki et al., 2017). Moreover,
periostin, a matricellular protein secreted in the
microenvironment, induces MT in GBMs and
increases malignant properties such as invasion
(Mikheeva et al., 2015).
Recent observations in lung cancer suggest that
EMT-dependent tumor cells are preferentially targeted
by immune checkpoint antagonists (Chen et al., 2014).
Also inflammatory stimuli themselves may lead to an
induction of cancer cell EMT (Ricciardi et al., 2015).
Vice versa, the role of EMT in tumor cell immuno-
genicity is not fully understood and currently contro-
versially discussed (Terry and Chouaib, 2015).
However, molecular networks regulating cellular plas-
ticity must be taken into account when designing new
immune system-based therapeutic avenues to fight can-
cer, including in GBM.
Summarizing, MT induction appears to function as
an adaptive response in glioma cells in order to
enhance treatment resistance or to facilitate escape
from cell toxic niches. Hence, targeting EMT pathways
will likely enhance antitumor efficacy of available
treatments in GBM.
2.1.5. Epigenetic regulation of MT and long noncoding
RNAs
miRNAs are 20- to 23-nucleotide noncoding RNAs
that post-transcriptionally regulate gene activity
through RNA silencing. Several miRNAs have been
identified as potent targets to impede EMT-TFs in
GBMs. Mostly negative correlations of miRNA
expression with tumorigenesis, tumor invasion, and
activation of EMT promoters have been described.
miR-7, miR-21, miR-23a, miR-124, miR-128a/b,
miR-200, and miR-221 are among the most studied
candidates. The field is heavily investigated, and for a
concise review about miRNAs regulating MT in
GBMs, see Møller et al. (2013). Interestingly, recent
observations indicate that miRNAs can indirectly influ-
ence MT in GBM by modulating their metabolism
(Hatziapostolou et al., 2013). TMZ treatment was
found to enhance autophagy leading to MT that
involves regulation by miR-517c. In glioma cells
expressing wild-type TP53, but not in a TP53-mutant
background, miR-517c inhibits the activation of autop-
hagy causing a disturbance of the nuclear translocation
of TP53 that in turn blocks mesenchymal transforma-
tion and autophagy-induced invasion (Lu et al., 2015).
Modulating miRNA homeostasis gains attraction as a
powerful approach in clinical translation in various dis-
eases and may be a very applicable way to target MT
in brain cancer oncology (Li and Rana, 2014).
Alterations in the chromatin packaging density is
another epigenetic mechanism to stereologically influ-
ence gene activity that is mediated through histone-
modifying enzymes. For example, histone deacetylase
5 (HDAC5) has been shown to promote MT in glio-
mas and regulate therapy resistance (Liu et al., 2015).
Of note, HDAC inhibition has emerged as a novel
strategy to overcome EMT and chemoresistance in
pancreatic cancer (Meidhof et al., 2015), but currently
little is known whether targeted histone modification
has therapeutic potential in GBM.
Promoter methylation is another important mecha-
nism for the control of gene transcription and EMT
regulation. Recent evidences occurred showing that
expression of ANXA2, an inducer of mesenchymal
transformation, is suppressed by promoter hyperme-
thylation and is associated with a better prognosis in
CpG hypermethylator phenotype (GCIMP) GBM
(Kling et al., 2016).
Finally, long noncoding RNAs (lncRNA) have
recently emerged as therapeutic targets in various dis-
eases. MT in GBM seems to be influenced by
lncRNAs as HOTAIR promotes GBM cell invasion
through the activation of WNT-dependent MT
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(Zhou et al., 2015). LncRNA ZEB1 antisense 1
(ZEB1-AS1), a noncoding antisense transcript con-
trolled by the ZEB1 promoter, serves as biomarker for
poor clinical prognosis in patients with GBM and aug-
ments cell invasion by inducing EMT activator ZEB1
(Lv et al., 2016). Also, lncRNA AB073614 can influ-
ence the expression of mesenchymal differentiation in
glioma cells although no effect on EMT-TFs expres-
sion was found (Li et al., 2016).
In summary, blocking (E)MT in cancer cells through
targeted modification of the epigenome or the house-
hold of lncRNAs may be an attractive therapeutic
strategy to impede tumor malignancy. This is particu-
larly promising as epigenetic alterations are reversible
and may be applied to transiently make tumors more
susceptible to traditional, clinically approved drugs.
Some promising ongoing clinical trials underline the
potential of epigenetic cancer therapy but targeted
delivery must be improved to limit off-target effects
(Nervi et al., 2015).
2.1.6. Methods for the detection of MT
Liquid biopsy is a minimal invasive procedure for
diagnosis and monitoring disease progression. It has
recently been identified that circulating brain cancer
cells (CBCCs) can be identified in the blood from
patients with GBM and those cells are highly tumori-
genic as shown in xenotransplantation experiments. Of
note, CBCCs exhibit an MT gene signature featuring
high SERPINE1, TGFB1, TGFBR2, and VIM expres-
sion (Sullivan et al., 2014). Moreover, noninvasive
imaging has emerged as a promising tool in precision
medicine. Recently, it was shown that the MT status
of GBM cells can be monitored by determining the
intracellular composition of choline derivatives using
high resolution of proton nuclear magnetic resonance
spectroscopy; the targeting of choline kinase 1a
(CHK1a) impaired MT (Koch et al., 2016).
A classical gene expression analysis is used to pre-
dict therapy success. As such, EMT gene expression
levels have been found to serve as predictive biomark-
ers for estimating the overall survival of radiation-trea-
ted GBM patients (Meng et al., 2014). Moreover,
cellular components excreted in exosomes show
promising results to be suitable for diagnosis in oncol-
ogy. Exosomes have even been found to carry an
‘EMT payload’ such as b-catenin or HIFs that
enhance the invasive and migratory capabilities of
recipient cells, thereby indirectly mediating cancer
metastasis and cellular dissemination (Syn et al.,
2016). Interestingly, exosomes of GBM cells were
found to reflect the hypoxic signature of the tumors
and transmit hypoxia-associated signals to receiving
cells (Kucharzewska et al., 2013).
Taken together, we hypothesize that traits of MT in
cellular metabolism or spread of proteome/RNA/DNA
into the blood or cerebral spinal fluid together with
recent technical advantages in noninvasive imaging
methods will contribute to the development of highly
personalized and minimally invasive diagnostic
approaches for patients with cancer extending the
importance of (E)MT not only as a therapeutic target
but also to diagnostic value.
2.2. MT in other cancers of the central nervous
system
Although less understood and investigated, several
strong indications exist that EMT-like processes and
related factors are involved in the development of
other brain malignancies, which will be discussed
below.
2.2.1. Medulloblastoma
Medulloblastoma (MB) is the most common primary
malignant pediatric brain tumor and can be subcatego-
rized into molecular subgroups (Cho et al., 2010).
SHH activation in GNP, the believed cellular origin of
MBs, as well as in MB cells induces the expression of
SNAI1, consequently activating the proto-oncogene N-
MYC to induce cellular transformation and prolifera-
tion (Colvin Wanshura et al., 2011). Hypoxia induces
MT in MB cells by activating SNAI1, vimentin, and
N-cadherin (Gupta et al., 2011). Moreover, ZEB1
expression is high in SHH-MB and inhibits granular
zone exit, which eventually contributes to tumor for-
mation (Singh et al., 2016).
2.2.2. Other brain tumor types
A comprehensive histological analysis of ZEB1 in
different brain tumors showed that ZEB1 activation
correlates with increasing tumor malignancy grade
(Kahlert et al., 2015). Also assessed by histology,
gliosarcomas express high levels of EMT-TFs such
as TWIST1 and SNAI2 (Nagaishi et al., 2012). His-
tone mutations as well as gene expression profiling
can differentiate diffuse intrinsic pontine glioma
(DIPG), one of the most devastating pediatric brain
tumors, into molecular subgroups including a mes-
enchymal branch (Castel et al., 2015; Puget et al.,
2012). Interestingly, subgrouping according to the
expression levels of EMT markers revealed a positive
prognostic value, indicating that MT in DIPGs may
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not play the classical protumorigenic role (Puget
et al., 2012).
Thus, although not extensively studied as yet, MT
appears to play a role in different brain tumor types.
3. MT in hematological malignancies
Tumors of the hematopoietic and lymphoid tis-
sues derive from either myeloid or lymphoid blood cell
lineages and give rise to leukemias or lymphomas,
respectively (Vardiman et al., 2009). Although the role
of MT in these malignancies originating from the
mesoderm is less well studied than for gliomas, there is
evidence for the involvement of EMT-TFs in their
malignant progression.
3.1. Lymphomas
Lymphomas occur mostly in lymph nodes and can be
subdivided in to two major groups, Hodgkin’s (HL)
and non-Hodgkin’s lymphoma (NHL). NHLs include
many different types such as B cell-derived Burkitt
lymphoma, diffuse large B-cell lymphoma (DLBCL),
mantle cell lymphoma (MCL), and T-cell lymphomas
(Sun et al., 2016).
3.1.1. MT inducers in B-cell malignancies
A role for ZEB1 in the regulation of B-cell lymphoma
protein 6 (BCL6), a master transcription factor in the
differentiation and development of B cells, has been
reported (Papadopoulou et al., 2010). ZEB1 together
with C-terminal binding protein binds to the BCL6
promoter leading to transcriptional suppression and
contribute to normal B-cell differentiation and devel-
opment. In malignancies, BCL6 expression in DLBCL
has been linked to better prognosis, and consistent
with this, immunohistochemical analyses of diagnostic
patient samples indicated a correlation between
nuclear ZEB1 staining and adverse clinical presenta-
tion and clinical outcome (Lemma et al., 2013). In
Helicobacter pylori-positive gastric DLBCL, which has
a better prognosis than negative counterparts, also a
role for ZEB1 has been implicated. Molecular analysis
revealed an association between elevated expression of
miR-200 and consequently inhibition of ZEB1 and an
increase in BCL6 expression in H. pylori-positive sam-
ples (Huang et al., 2014). This provides a further link
between ZEB1 expression and a more aggressive
DLBC phenotype. Involvement of miR-200 also has
been described in a radiation-induced thymic lym-
phoma (RITL) mouse model. RITL samples showed a
decrease in miR-200c and forced expression of this
miRNA resulted in cell death, which was associated
with suppression of the polycomb group protein BMI1
(Cui et al., 2014).
In MCL, also an important role for ZEB1 in
tumor aggressiveness has been identified. MCL is a
rare B-cell malignancy demonstrating resistance to
treatment and poor prognoses. In half of the MCL
cases, the canonical WNT pathway is activated, and
recently, this was linked to ZEB1 expression and a
shorter overall survival (Sanchez-Tillo et al., 2014).
Beta-catenin could bind and activate the ZEB1 pro-
moter and ZEB1 protein on its turn activates prolif-
eration and antiapoptotic genes while suppressing
proapoptotic ones. Moreover, ZEB1 contributes to
chemoresistance by enhancing expression of drug
efflux pathways and consequently silencing of ZEB1,
resulting in sensitization to doxorubicin in a xeno-
graft mouse model.
3.1.2. MT inducers in T-cell lymphomas
Sezary syndrome (Sz) is a rare cutaneous T-cell lym-
phoma (CTCL) that primarily manifests in the skin.
Analyses of the T cells in Sz patients and normal con-
trols revealed particularly high selective expression of
EphA4 and TWIST as well as in other types of CTCL
(van Doorn et al., 2004). More recently, promoter
DNA hypomethylation of TWIST has been associated
with protein overexpression (Wong et al., 2015).
In addition to TWIST, also ZEB1 has been sug-
gested to be involved in Sz CTCL. Genomic analyses
revealed ZEB1 gene deletions in more than half of the
cases although the relevance of this deletion needs to
be further explored (Wang et al., 2015b). Recently, a
possible mechanism was provided. Biopsies of patients
with CTCL demonstrated increased interleukin (IL)-15
activity that appears instrumental for disease progres-
sion. Interestingly, ZEB1 has been identified as a
potent transcriptional repressor of IL-15 and hyperme-
thylation of its binding region in the IL-15 promoter
prevents suppression of IL-15 production in CTCL
and thus progression (Mishra et al., 2016).
A chromosomal translocation giving rise to an
abnormal nucleophosmin (NPM)-anaplastic lymphoma
kinase (ALK) fusion protein is characteristic for pedi-
atric anaplastic large cell lymphoma (ALCL). TWIST1
was found aberrantly expressed in ALK + ALCL cells,
which could be attributed to constitutive STAT3 sig-
naling in this T-cell malignancy (Zhang et al., 2012).
TWIST1 knockdown decreased invasiveness and sensi-
tized for an ALK inhibitor in cell culture models, thus
linking TWIST1 with malignant progression and ther-
apy resistance of this tumor.
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Binding of ZEB1 to SMAD3 and SMAD7 enhances
TGF-b signaling. In accordance with that, downregu-
lation of ZEB1 resulted in resistance to the growth-
suppressive effect of TGF-b in adult T-cell leukemia/
lymphoma (ATLL) (Nakahata et al., 2010). In this
context, it is interesting to note that ZEB1 is involved
in the regulation of normal T-cell development. Mice
with homozygous C-terminal deletions in Zeb1 were
among others characterized by small thymus and a
reduction in early T-cell progenitors (Higashi et al.,
1997). This provides another hint that ZEB1 is an
important regulator of differentiation pathways that
are deregulated in lymphoid malignancies.
3.2. Myelomas
Multiple myeloma (MM) originates from plasma
cells that normally produce antibodies. It is the sec-
ond most common hematological malignancy that
still remains incurable. Hypoxia, a well-known trig-
ger of EMT in solid tumors, also is able to induce
this process in MM cells. Hypoxia in bone marrow
(BM) niches resulted in MT in MM cells character-
ized by a decrease in E-cadherin levels and increases
in EMT-inducing proteins such as SNAI1 and TGF-
b, which positively correlated with levels of circulat-
ing MM cells in the peripheral blood. In addition,
hypoxia-induced CXCR4 resulted in homing of MM
cells to the BM, thus completing a malignant dissem-
ination–colonization cycle (Azab et al., 2012). The
involvement of MT in disease spreading is also
supported by the finding that TWIST1 expression is
elevated in skeletal extramedullary disease of
patients with MM and correlates with a lower rate
of progression-free survival (Yang et al., 2016). In
another study, IL-17 is reported to enhance cell pro-
liferation and repress cell adhesion by inducing MT
evidenced by downregulation of E-cadherin and
upregulation of SNAI1, SNAI2, and vimentin. In
addition, IL-17 repressed miR-192 that targets the
IL-17 receptor, thus providing a regulatory feedback
loop (Sun et al., 2014). Based on these findings, it is
postulated that inhibition of MT may provide thera-
peutic benefit in MM.
3.3. Leukemias
The involvement of TWIST2 in leukemia was first
described by Raval et al. (2005) in chronic lympho-
cytic leukemia (CLL). Absence of TWIST2 expres-
sion correlated with TWIST2 promoter methylation
in a proportion of CLL cases. The epigenetic inacti-
vation of TWIST2 also has been reported to
modulate disease progression in childhood acute lym-
phoblastic leukemia. Promoter methylation of
TWIST2 was found in more than half of the cases
and restoration of TWIST2 expression resulted in
growth inhibition and apoptosis in vitro suggestive of
tumor-suppressive functions (Thathia et al., 2012).
Consistent with this notion is a report by Zhang
et al. (2015), showing that in acute myeloid leukemia
(AML) in around 30% of examined cases hyperme-
thylation of TWIST2 occurred leading to reduced
expression of both TWIST2 and the cyclin-dependent
kinase inhibitor p21. TWIST2 activates p21 expres-
sion among other tumor suppressor genes and sup-
presses oncogenic activity.
In contrast to TWIST2, TWIST1 was linked with
enhanced aggressiveness of leukemic cells. In chronic
myeloid leukemia (CML), upregulation of TWIST1
was seen in patient samples obtained from imatinib-
resistant patients. A link between imatinib resistance
and TWIST1 exists, as in vitro knockdown of TWIST1
expression in CML cells resulted in sensitization for
imatinib (Cosset et al., 2011). TWIST1 also has been
identified as a direct regulator of BMI, which is known
for its role in maintaining self-renewal, a characteristic
of cells with a high proliferative potential or stem cells.
Analyses of TWIST1 and BMI expression in AML
revealed a positive correlation associated with
enhanced proliferation and apoptosis resistance in vitro
(Chen et al., 2015). In addition, enhanced TWIST1
expression was found in CML leukemic stem cells that
decreased upon differentiation. Downmodulation of
TWIST1 reduced their colony-forming capacity, pro-
viding further evidence for TWIST1 involvement in
leukemia stem cells and disease progression (Wang
et al., 2015c).
Recently, using an inducible MLL-AF9-driven AML
mouse model representing an aggressive type of AML,
elevated expression of EMT-related genes has been
observed. Knockdown of ZEB1 reduced the invasive
properties of this aggressive tumor (Stavropoulou
et al., 2016). In another study, shRNA screens to iden-
tify genetic dependencies for AML resulted in the iden-
tification of ZEB2. ZEB2 downregulation impaired
proliferation and caused irregular differentiation of
AML cells (Li et al., 2017). The implications of MT in
leukemia also is demonstrated by a report showing
that an increase in HIF1-related signaling is associated
with genes involved in EMT, further linking EMT-like
processes with leukemia progression (Percio et al.,
2014).
Together, the above illustrates that EMT inducers
and EMT-TFs play important roles in the progression
of hematological tumors.
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4. EMT- and MET-related processes in
sarcomas
Sarcomas are uncommon malignancies that arise from
mesenchymal cell types and develop in or from bone,
cartilage, or connective tissue, such as muscle, fat,
peripheral nerves, and fibrous or related tissues
(Taylor et al., 2011). Together, sarcomas account for
nearly 21% of all pediatric solid cancers and less than
1% of all adult solid malignant cancers (Surveillance,
Epidemiology, and End Results (SEER) program
(Burningham et al., 2012). Sarcomas can be pre-
dominantly grouped into two major groups, namely
malignant bone tumors and soft tissue sarcomas
(Lahat et al., 2008).
As sarcomas are mesenchymal by default, some
studies have addressed whether EMT inducers are
involved in tumorigenesis. Indeed, SNAI1 expression
is associated with worse overall survival in sarcomas.
In addition, ectopic expression of SNAI1 has tumori-
genic activity in fibroblasts and a role for SNAI1
in the generation of sarcomas has been suggested
(Alba-Castellon et al., 2014). Similarly, in malignant
bone tumors, osteosarcomas, elevated levels of ZEB1
are detected compared to normal bone and ZEB1
expression is higher in metastatic osteosarcoma in
comparison with the group without metastases (Shen
et al., 2012). A recent study shows that TGF-b treat-
ment can trigger MT of osteosarcoma cells in vitro
involving estrogen-related receptor a-dependent activa-
tion of SNAI1 (Chen et al., 2016). Thus, MT may be
involved in the onset and progression of sarcomas but
more studies are required for further substantiation.
However, most studies have focused on studying the
involvement of the reverse process, MET, in malig-
nancy of sarcomas (see also Fig. 3).
4.1. Epithelial differentiation and prognosis in
sarcomas
A number of studies have reported the occurrence of
local epithelial differentiation in sarcomas by deter-
mining the expression of epithelial markers. Sato and
coworkers were one of the first showing E-cadherin
expression in various bone and soft tissue sarcomas
(Sato et al., 1999). Likewise, in synovial sarcomas, the
expression of epithelial markers like E-cadherin and b-
catenin was detected and a decrease in their expression
was linked to a high potential of recurrence or metas-
tasis and poor prognosis (Saito et al., 2004, 2006).
Ewing sarcoma/primitive neuroectodermal tumor, a
primitive bone and soft tissue sarcoma, frequently dis-
plays partial epithelial differentiation evidenced by the
expression of tight junction proteins claudin-1 and
ZO-1, although being negative for E-cadherin expres-
sion (Schuetz et al., 2005). In osteosarcomas, expres-
sion of E-cadherin is potentially useful as a prognostic
marker for patient survival (Nakajima et al., 2008).
An MET transcription profile appeared prognostic for
improved survival in sarcoma patients (Yang et al.,
2010). This is in agreement with another study show-
ing that sarcoma patients with higher levels of the
epithelial marker, E-cadherin, have improved survival
in comparison with those with low or no E-cadherin
(Wang et al., 2015d). It should be noted that despite
the increase in epithelial markers in sarcomas, mes-
enchymal markers continue to be abundantly
expressed (Saito et al., 2004; Yang et al., 2010).
Evidence is growing for the utilization of miRNA
profiling in the diagnosis of soft tissue sarcomas (Fuji-
wara et al., 2014). As miRNAs are known for regulat-
ing EMT/MET processes, it is likely that they affect
the mesenchymal status of sarcomas. Only few studies
have explored this (see under 4.2) and greater under-
standing of the biology of miRNAs in sarcomas will
undoubtedly contribute the advancement of novel
diagnostic and therapeutic approaches.
4.2. Mechanisms of MET in sarcomas
Additional evidence for the occurrence of MET in sar-
comas has been obtained by functional studies aiming
at elucidation of the underlying mechanisms of epithe-
lial differentiation. In synovial sarcoma, the fusion
proteins SYT-SSX1 and SYT-SSX2 are able to inter-
act with SNAI1 or SNAI2, thus preventing their sup-
pressive effects on E-cadherin expression leading to the
acquisition of epithelial features indicative of MET
(Saito et al., 2006). An integrated proteomics and
genomics analyses in soft tissue leiomyosarcomas
identified SNAI2/SLUG as a negative regulator of
E-cadherin expression; knockdown of SNAI2 increased
E-cadherin and decreased vimentin expression that was
associated with a decrease in proliferation and inva-
sion (Yang et al., 2010). A more recent study demon-
strates that the combined expression of miR-200
family members and upregulation of an epithelial gene
activator, grainyhead-like transcription factor 2
(GRHL2), drive MET in sarcomas. This study showed
that both GRHL2 overexpression and downregulation
of ZEB1 by either RNAi-mediated silencing or miR-
200 overexpression act in a synergistic manner to
control the upregulation of epithelial genes, including
E-cadherin, and consequently MET (Somarelli et al.,
2016). MET-like phenomena also have been detected
in chondrosarcomas where a downregulation of
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SNAI1/SNAIL led to a gain of mesenchymal markers
like E-cadherin, desmocollin, maspin, and 14-3-3r that
in part were regulated epigenetically by cytosine
methylation (Fitzgerald et al., 2011). Yet another
study demonstrated that the expression of T-cell
immunoglobulin mucin domain molecule-3 (Tim-3) in
osteosarcomas contributes to the mesenchymal status.
Tim-3 downregulation significantly suppressed
osteosarcoma cell (MG-63) proliferation and metasta-
sis via inhibition of the NF-jB/SNAI1 signaling path-
way causing epithelial differentiation (Feng and Guo,
2016).
Phosphoglucose isomerase (PGI), a glycolytic
enzyme catalyzing an interconversion between glucose
and fructose, extracellularly behaves as a cytokine that
includes autocrine motility factor (AMF). AMF/PGI
has been typically associated with induction of EMT.
It has been shown in osteosarcoma that the silencing
of AMF/PGI reduces the production and secretion of
TGF-b2 and TGF-b3 resulting in downregulation of
SNAI1 that can elevate E-cadherin expression leading
to MET. Thus, silencing of AMF/PGI might con-
tribute toward the loss of malignancy in these cancers
through differentiation via MET (Niinaka et al.,
2010). Similar to this study, AMF/PGI appears to reg-
ulate the MET process in human lung fibrosarcoma
cells (Funasaka et al., 2007). In Saos-2 osteosarcoma
cells, transfection of WNT receptor low-density
lipoprotein receptor-related protein 5 (LRP5) caused a
marked upregulation of E-cadherin and downregula-
tion of N-cadherin and was associated with reduced
activity of the transcription factors SNAI2 and Twist
(Guo et al., 2007). A detailed overview of the
upstream signaling and transcription factors involved
in the initiation and regulation of MET in sarcoma is






















Fig. 3. Initiation and regulation of MET in sarcomas. Summary of mechanisms identified in different sarcoma subtypes (see also text).
Upstream signaling involving the oncogenic fusion proteins SYT-SSX1 and SYT-SSX2 downregulates SNAI1 or SNAI2 leading to an increase
in E-cadherin expression, a readout for MET. Downregulation of Tim-3 leads to epithelial differentiation via suppressing NF-jB/SNAI1
signaling. The silencing of the AMF/PG1 complex results in enhanced secretion of TGF-b2 and TGF-b3, which in turn can induce SNAI1
giving way to an elevated E-cadherin expression. LRP5, a component of WNT signaling, can upregulate E-cadherin, which is brought about
by the suppression of SNAI2 and TWIST. mir200 exerts a dual effect as its overexpression can lead to GRHL2 overexpression and
downregulation of ZEB1 resulting in elevated E-cadherin levels. Together, all these signals mostly lead to an elevation in E-cadherin and
consequently MET, which has been linked with a better patient prognosis.
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Together, these findings indicate the involvement of
the well-known EMT inducers in either the mainte-
nance of mesenchymal differentiation or the onset of
epithelial differentiation upon loss of activity, thus
explaining the observed heterogeneity in this mes-
enchymal neoplasm.
4.3. MT/MET and therapy in sarcomas
Several studies have implicated the involvement of
MT and MET in sensitivity of sarcomas to therapies.
The exposure of osteosarcoma cells to cisplatin gener-
ates a more resistant and mesenchymal phenotype as
was shown in in vitro and in vivo studies. SNAI1
appeared to be the major factor mediating this cis-
platin-induced MT (Fang et al., 2016). The use of
radiosensitizers like zoledronic acid can sensitize
osteosarcoma cells to c-irradiation. Sensitization is
associated with impaired cell migration, invasion and
reduced expression of EMT markers like vimentin,
MMP-9, and SNAI2, indicating epithelial differentia-
tion and reduced malignancy (Kim et al., 2016). An
interesting drug against sarcomas is the naturally
derived bioactive compound withaferin-A (WFA) that
targets vimentin. WFA induces marked apoptosis and
vimentin cleavage in vimentin-expressing tumor cells.
In a cell panel representing different types of sarcoma,
high sensitivity to WFA was observed linked to cas-
pase-dependent degradation of vimentin and apoptosis
activation. The proapoptotic response was suppressed
following vimentin knockdown or by caspase block-
ade. WFA also significantly blocked soft tissue sar-
coma growth, local recurrence, and metastasis in
xenograft models (Lahat et al., 2010). This finding
holds great promise for the use of WFA and other
antivimentin drugs as a potential therapeutic option in
soft tissue sarcomas.
5. Concluding remarks
Increasing evidences occur that similar, well-coordi-
nated processes of EMT and its counterpart MET
extend to the biology of nonepithelial malignancies.
In brain tumors, hematopoietic tumors, and sarco-
mas, EMT-like processes also contribute to malig-
nancy, as outlined above. In these nonepithelial
cancers, MT is controlled, equally as found in carci-
nomas, by comparable cell autonomous or TME-
derived signals leading to the modulation of the
well-known EMT-TFs. Although not as extensively
investigated for all nonepithelial tumors and best in
GBM, overall MT induction is associated with
increased stem cell and invasive/metastatic potential
and therapy resistance. Correspondingly, biomarkers
for MT have been linked with worse clinical outcome
in these cancers. However, particularly in sarcomas,
the opposite process MET occurs frequently resulting
in more favorable tumor properties. A therapeutic
shifting of sarcomas to a more epithelial-like state
could attenuate their aggressiveness and improve
patient outcome. Given the fact that recent observa-
tions suggest cancer EMT can be monitored through
noninvasive or minimal invasive technologies, it will
be interesting to correlate the preclinical observations
with clinical cohorts and determine possible clinical
implications.
Recent observations suggest that the distinct balance
between EMT and MET in the form of a hybrid
epithelial/mesenchymal (E/M) cellular phenotype par-
ticularly promotes cancer cell aggressiveness, which is
more drastic than fully committed EMT (Jolly et al.,
2016). Importantly, the existence of E/M condition(s)
in cells of tumors originating from tissues other than
the epithelial layer has not been studied comprehen-
sively. Studies to investigate the intermediate stage of
E/M in those tumor types are needed to verify whether
such a reciprocal, triple phenotypic classification exists
and has similar tumor progressive properties as for
epithelial cancers.
Given the complexity of EMT/MET networks and
the ability of cancer cells to adapt to stress situations,
targeting one protein or pathway may not be sufficient
to completely impede EMT. Anti-EMT therapy should
therefore be supported by other (targeted) therapies.
In conclusion, further studies are required to unravel
the mechanisms governing MT/MET in these nonep-
ithelial cancers and for being suitable as prognostic
markers or therapeutic targets in order to improve
their clinical management.
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